<DOC>
	<DOCNO>NCT00901368</DOCNO>
	<brief_summary>Double blind , multinational , multicentre , randomise , 2 arm parallel group study</brief_summary>
	<brief_title>FACTO Study ( Foster® As Complete Treatment Option )</brief_title>
	<detailed_description>Aim present investigation demonstrate clinical equivalence fluticasone plus salmeterol 500/100 µg daily equipotent dose CHF1535 maintain asthma control patient adequately control fluticasone plus salmeterol mentioned daily dose .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Asthmatic patient enrol Visit 1 runin period meet follow criterion : 1 . Written inform consent obtain 2 . Adult male female ( ≥18 ≤65 year ) 3 . Clinical diagnosis control asthma accord Global Strategy Asthma Management Prevention ( GINA ) revise version 2007 previous week study entry : daytime symptom ( twice less/week ) limitation activity nocturnal symptoms/awakenings need reliever/rescue medication ( twice less/week ) lung function ( FEV1 ) &gt; 80 % predict personal best ( know ) 4 . Patients treat fluticasone 500 µg + salmeterol 100 µg daily ≥ 4 week 5 . A cooperative attitude ability correctly use device complete diary card . Patients enrol visit 1 runin period meet follow criterion : 1 . Inability carry pulmonary function test ; 2 . Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) define National Heart Lung Blood Institute/World Health Organisation ( NHLBI/WHO ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ; 3 . History near fatal asthma ; 4 . Evidence severe asthma exacerbation symptomatic infection lower airways previous six month ; 5 . Three course oral corticosteroid hospitalisation due asthma previous 6 month ; 6 . Patients treat longacting β2agonists ( LABAs ) salmeterol , anticholinergic , leukotriene antagonist previous 4 week ; 7 . Current smoker recent ( less one year ) exsmokers define smoke least 15 packs/year ; 8 . Clinically significant unstable concurrent disease : e.g . uncontrolled hyperthyroidism , uncontrolled diabetes mellitus endocrine disease ; significant hepatic impairment ; significant renal impairment ; significant pulmonary disease ; cardiovascular disease ; gastrointestinal disease ; neurological disease ; haematological disease , autoimmune disorder , may interfere patient 's safety , compliance , study evaluation , accord investigator 's opinion ; 9 . Patients serum potassium value ≤ 3.5 mEq/L 10 . Patients QTc interval ( Bazett 's formula ) high 450 msec screen visit 1 ; 11 . Cancer chronic disease prognosis &lt; 2 year ; 12 . Female subject : pregnant active desire pregnant , lactate mother lack efficient contraception subject childbearing potential ( i.e . contraceptive method oral contraceptive , IUD , tubal ligature ) . A pregnancy test urine carry woman fertile age screen 13 . Significant alcohol consumption drug abuse ; 14 . Patients treat betablockers regular use ; 15 . Patients treat monoamine oxidase inhibitor , tricyclic antidepressant Selective Serotonin Reuptake Inhibitors ( SSRIs ) , unless already take stable dos screen visit 16 . Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient ; 17 . Patients unlikely comply protocol unable understand nature , scope possible consequence study ; 18 . Patients receive investigational new drug within last 12 week ; 19 . Patients asthma exacerbation runin period also exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>